Loading data for INKT — first visit, this takes a few seconds.
MiNK Therapeutics, Inc. (INKT)
NasdaqCM: INKT
· Real-Time Price · USD
11.90
+0.38 (3.30%)
At close: Sep 09, 2026, 8:00 PM
The price, the headline numbers and the latest news, in one place.
MiNK Therapeutics, Inc. (INKT) Stock Price, Analysis & Data
No data available
| Bid | 8.73 |
| Market Cap | 60.7M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -11.4M |
| 0.49 | |
| -2.45 | |
| n/a | |
| -4.5 | |
| P/B (ttm) | -4.32 |
| P/S (ttm) | 0.00 |
| Earnings Date | n/a |
| Ask | 15.12 |
| Volume | 16,765 |
| Avg. Volume (20D) | 13,983 |
| Open | 11.54 |
| Previous Close | 11.52 |
| Day's Range | 11.54 - 12.15 |
| 52-Week Range | 8.48 - 16.98 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About INKT
MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company develops agenT-797, an off-the-shelf, allogeneic, and native iNKT cell therapy that is in Phase 2 clinical trial for the clinical safety and efficacy of the com...
Industry Biotechnology
Sector Healthcare
IPO Date Oct 15, 2021
Employees 15
Stock Exchange NasdaqCM
Ticker Symbol INKT
Website https://minktherapeutics.com
Financial Performance
In 2025, MiNK Therapeutics's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -12.49M, an increase of 15.85%.
Financial StatementsEarnings Surprise
MiNK Therapeutics has released their quarterly earnings on Invalid Date:
- Revenue of n/a misses estimates by $0, with NaN% YoY growth.
- EPS of misses estimates by , with NaN% YoY growth.
Page 1 of 2